Nonobstetric critical illness during pregnancy presents unique challenges due to the complex interplay between maternal physiological adaptations and acute pathology. This review synthesizes current evidence on maternal hemodynamic changes in the context of nonobstetric critical illness, elucidating pathophysiology, risk factors, clinical manifestations, and management strategies. Recent advances and guideline recommendations are discussed with an emphasis on clinical decision-making for optimizing maternal and fetal outcomes.
Pregnancy induces profound hemodynamic changes that support fetal development yet increase maternal vulnerability to critical illness. When nonobstetric conditions necessitate intensive care, the altered maternal cardiovascular profile complicates diagnosis, monitoring, and therapeutic interventions. Understanding these changes is essential for clinicians managing pregnant patients with acute medical or surgical conditions, as both maternal and fetal well-being depend on precise hemodynamic management.
Globally, nonobstetric critical illness accounts for approximately 0.5–1% of all pregnancies, with sepsis, trauma, cardiac disorders, and respiratory failure being predominant causes. ICU admission rates among pregnant individuals have risen in high-resource settings, reflecting increased maternal age, comorbidities, and improved detection. Maternal mortality and morbidity related to nonobstetric critical illness remain substantial, with cardiovascular collapse, multi-organ dysfunction, and preterm delivery as leading adverse outcomes. Epidemiological data underscore the importance of early recognition and specialized management of this patient population.
Physiological adaptations of pregnancy include increased plasma volume (by up to 50%), elevated cardiac output (30–50%), decreased systemic vascular resistance, and altered colloid oncotic pressure. These changes are further modulated by hormonal influences such as progesterone and relaxin. In critical illness, particularly sepsis or shock, these adaptations may exacerbate or mask volume depletion, hypoperfusion, or cardiac dysfunction. For example, the hyperdynamic circulatory state of pregnancy may conceal early hypovolemia, while increased baseline heart rate and reduced vascular resistance complicate assessment of shock severity. Respiratory adaptations, including decreased functional residual capacity and increased oxygen consumption, further influence hemodynamic responses during acute illness.
Several factors elevate the risk of adverse hemodynamic responses during nonobstetric critical illness in pregnancy. Advanced maternal age, pre-existing cardiac or renal disease, obesity, multiple gestation, and placental abnormalities compound vulnerability. Iatrogenic factors, such as aggressive fluid resuscitation or inappropriate vasopressor use, may precipitate pulmonary edema or uteroplacental hypoperfusion. Additionally, the presence of sepsis, hemorrhage, or acute respiratory distress syndrome (ARDS) significantly increases the risk of cardiovascular instability and adverse maternal-fetal outcomes.
Maternal hemodynamic compromise in nonobstetric critical illness often presents subtly due to physiological compensation. Tachycardia, hypotension, altered mental status, decreased urine output, and signs of end-organ hypoperfusion may be variably expressed. Classical symptoms such as dyspnea or chest discomfort may overlap with normal pregnancy complaints, necessitating a high index of suspicion. Fetal distress, manifested as abnormal heart rate patterns, may be an early indicator of maternal compromise, emphasizing the importance of simultaneous fetal monitoring in critically ill pregnant patients.
Diagnosis requires integration of clinical assessment with advanced hemodynamic monitoring. Noninvasive modalities, such as echocardiography, Doppler ultrasound, and continuous blood pressure monitoring, are preferred to minimize fetal risk. Laboratory evaluation includes lactate, arterial blood gases, and markers of end-organ function. Invasive monitoring (e.g., central venous pressure, pulmonary artery catheterization) is reserved for refractory or complex cases, given potential risks. Imaging, when indicated, should employ modalities with minimal ionizing radiation exposure, such as MRI or ultrasonography.
Management prioritizes stabilization of maternal hemodynamics while minimizing fetal compromise. Volume resuscitation must balance the risk of fluid overload with the need to restore perfusion. Crystalloids are first-line, with colloids reserved for persistent hypotension. Vasopressors (e.g., norepinephrine) are titrated to maintain mean arterial pressure >65 mmHg, with close surveillance for uteroplacental perfusion. Inotropes may be necessary for cardiac dysfunction. Mechanical ventilation strategies target maternal oxygenation and normocapnia, with low tidal volumes to mitigate barotrauma. Pharmacologic interventions must consider teratogenicity and placental transfer. Multidisciplinary collaboration, involving critical care, obstetrics, cardiology, and neonatology, is essential for individualized care.
Recent advances include noninvasive cardiac output monitoring and point-of-care ultrasound for real-time hemodynamic assessment. Biomarkers such as proBNP and troponin are increasingly utilized to differentiate cardiac from non-cardiac etiologies of shock. Protocol-driven management, early goal-directed therapy, and sepsis bundles have demonstrated improved outcomes in pregnant populations. Emerging therapies, such as extracorporeal membrane oxygenation (ECMO), are considered in refractory cases, with accumulating experience supporting their judicious use. Research continues on optimal vasopressor selection and the role of endothelial-targeted therapies in sepsis-associated maternal shock.
International societies, including the Society of Critical Care Medicine and the American College of Obstetricians and Gynecologists, recommend individualized hemodynamic targets, early multidisciplinary involvement, and the use of noninvasive monitoring when feasible. Guidelines emphasize the importance of fetal surveillance, judicious fluid management, and risk-benefit analysis in pharmacologic therapy. Early delivery is considered only when maternal status deteriorates despite maximal support or fetal compromise is evident. Protocols for sepsis, ARDS, and shock are adapted for pregnancy with heightened attention to maternal-fetal physiology.
Nonobstetric critical illness during pregnancy necessitates a nuanced understanding of maternal hemodynamics to ensure optimal outcomes for both mother and fetus. Integration of recent evidence, advanced monitoring, and multidisciplinary care is paramount. Ongoing research and guideline refinement will further enhance management strategies in this high-risk population.
1.
A small rise in cancer was observed following the 1986 Chernobyl accident.
2.
CAR-T Induces Deep, Durable Remission in Smoldering Myeloma
3.
Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.
4.
Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial
5.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
1.
Developmental Regulation of Pediatric Red-Cell Production
2.
Exploring the Benefits of Flexible Sigmoidoscopy: A Revolutionary Way to Detect Colorectal Cancer
3.
Robotic Intratumoral Resection for Organ Preservation: Current Evidence and Clinical Implications
4.
Clinical Analysis of Prostate Cancer
5.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Signs and Symptoms of Leukemia
2.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
The Role of Hemoglobin in Maintaining Healthy Oxygen Levels
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation